Search for a trial

A Phase 1/2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 (MAGE-A1-Directed TCR-Transduced Autologous CD8+ T-cells) in Patients with HLA-A*02:01 Genotype and Advanced-Stage/Metastatic, MAGE-A1+ Solid Tumors that Either Have No Further
Approved Therapeutic Alternative(s) or are not Eligible for them or are in a Non-Curable State and Have Received a Minimum of Two Lines of Systemic Therapy

Phase 1 Part (Dose-escalation and Expansion):Primary objective:To evaluate the safety and tolerability of TK-8001Secondary objectives:To evaluate the preliminary anti-tumor activity of TK-8001 To determine the recommended Phase 2 dose (RP2D) of TK-…

Taste and smell dysfunction in patients more than two years after start of immune checkpoint inhibitor therapy

To determine the prevalence of taste and smell dysfunction in patients more than two years after start of ICI therapy - compared with a control group of caregivers. Secondary objective: to assess the association between taste and smell dysfunction,…

A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α related Genetic Alterations

This study has been transitioned to CTIS with ID 2023-504853-11-00 check the CTIS register for the current data. To evaluate the ORR of belzutifan per RECIST 1.1 by blinded independent central review (BICR).

A First-In-Human study of 89ZR-DFO-REGN5054 (anti-CD8) Positron Emission Tomography in patients with solid malignancies treated with cemiplimab

The primary objective:To determine the safety and tolerability of 89Zr*DFO*REGN5054 alone and in combination with cemiplimab.Secondary ObjectivesFor Part A:• To characterize the radioactivity pharmacokinetic (PK) profile of 89Zr DFO REGN5054• To…

A Phase 1/2, open label, first-in-human, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR445877 administered as monotherapy or in combination with other anticancer therapies in adults with advanced solid tumors

This study has been transitioned to CTIS with ID 2023-507141-28-00 check the CTIS register for the current data. Primary- Dose escalation: To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), recommended dose(s), and the…

Ultrasound-guided resection of buccal mucosal carcinomas - a multicenter study

The aim of this research is to decrease the number of involved margins, resulting in less adjuvant therapy and less local recurrences.

Mapping of Sentinel lymph node drainage Using SPECT/CT to tailor highly selective elective nodal irradiation in node-negative neck of patients with head and neck cancer - SUSPECT-2

To prospectively evaluate the oncologic safety of selective SPECT/CT-guided ENI in a larger cohort of HNSCC patients

A randomized, multi-center, open-label, active-controlled Phase 3 trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) versus octreotide LAR or lanreotide ATG in patients with gastroenteropancreatic neuroendocrine tumors

This study has been transitioned to CTIS with ID 2023-508723-12-00 check the CTIS register for the current data. Primary Objective• To assess superiority of treatment with CAM2029 compared to treatment with octreotide long-acting release (LAR) or…

A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in
patients with advanced solid tumors harboring the KRAS G12C mutation

This study has been transitioned to CTIS with ID 2023-508073-87-00 check the CTIS register for the current data. Primary objectives:Dose Escalation• To assess the safety and tolerability of JDQ443 single agent and JDQ443 in combination with TNO155,…

Phase 1/2a, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid tumors

This study has been transitioned to CTIS with ID 2024-514962-38-00 check the CTIS register for the current data. -To assess the safety and tolerability of CLDN6 CAR-T +/- CLDN6 RNALPX and to assess the comparability of CLDN6 CAR-T from the manualand…

A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects with Advanced Solid Tumours.

Principal objectives: •To determine the safety, tolerability and recommended dose of FP- 1305 in subjects withadvanced solid tumours of the selected tumourtypes without standard treatment options.• To determine the safety, tolerability and early…

A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokinetics of intravenous infusion of CP-506, a tumor agnostic Hypoxia Activated Prodrug in patients with HRD/FAD solid tumors or tumor types with high incidence of HRD/FAD in monotherapy or in combination with carboplatin or patients with solid tumor and oligoprogressive disease receiving immune checkpoint inhibitors (ICI): a phase I-IIa

This study has been transitioned to CTIS with ID 2023-506818-45-00 check the CTIS register for the current data. The study*s primary objective is to assess the safety and tolerability of CP-506 alone or in combination therapy. The 3 different…

An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments

The purpose of this study is to allow collection of safety and tolerability data in subjects benefitting from treatment with spartalizumab as a single agent or in combination with other study treatments in a pre-defined (Appendix Section 16.1)…

A Phase I Study to Assess Biodistribution of 89Zr-CB307 in PSMA+ and PSMA-Tumour Lesions

To assess the safety of 89ZrCB307To assess 89Zr-CB307 uptake by PET scan

Evaluating the safety of shortened infusion times for different oncological immunotherapies; An observational prospective study

This study has been transitioned to CTIS with ID 2024-518878-14-01 check the CTIS register for the current data. Primary ObjectiveTo determine the incidence and grading of infusion related/hypersensitivity reactions reported per drug using the…

An Open Label Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies

The primary objectives are to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RP2D) of ABBV-621 and to evaluate pharmacokinetics (PK) of (A) single agent ABBV-621; and (B) the combination of ABBV-621 and venetoclax in…

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin, HuMax®-AXL-ADC) in patients with solid tumors.

4.1 Primary Objective• To determine the MTD and to establish the safety profile of enapotamab vedotin in a mixed population of patients with specified solid tumors. 4.2 Secondary Objectives• To evaluate the safety laboratory parameters of enapotamab…

A Phase Ib, open label, multicenter study of the safety and efficacy of MIW815 (ADU-S100) administered by intratumoral injection with PDR001 to patients with advanced/metastatic solid tumors or lymphomas

Primary: To characterize safety and tolerability of MIW815 (ADU-S100) given with PDR001 and identify recommended doses and schedule for future studies.Secondary: Anti-tumor activity. Pharmacodynamics (PD). Pharmacokinetics (PK).

PHARMACOKINETICS OF APREPITANT, DEXAMETHASONE AND THEIR INTERACTION IN CHILDREN WITH CHEMOTHERAPY INDUCED NAUSEA AND VOMITING: A PILOT STUDY

we propose a pilot PK study to assess: 1) The interaction between aprepitant and dexamethasone in children using both antiemetogenic agents at the same time, to optimize the dose of both agents in children of different age groups.2) The feasibility…

A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma - BEACON-Neuroblastoma Trial

This study has been transitioned to CTIS with ID 2024-518931-12-00 check the CTIS register for the current data. Primary:- To test whether bevacizumab added to a backbone chemotherapy regimen (temozolomide or irinotecan-temozolomide or topotecan-…